Natural Capsules needs ₹25-30 cr more for API plant, revising earlier claims
Management guided ₹274 cr in FY27 revenue but admitted a key facility isn't fully capitalized. Projected debt heads toward ₹110 cr through FY28.
What's new
- Management revised its API plant funding story, now saying ₹25-30 cr more is needed for clean-room facilities.
- FY27 revenue target is ₹274 cr, aiming to bounce back from a ₹24.66 cr net loss in FY26.
- A 68% combined US tariff on HPMC capsules is a major headwind for exports.
Why this matters
The revised capex need contradicts earlier statements that the plant was fully capitalized. For a loss-making nano-cap, finding an extra ₹25-30 cr while debt is set to rise toward ₹110 cr is a real funding question. Management's credibility on hitting targets is already dented by a significant miss on prior API sales guidance.
What we're watching
- Where the ₹25-30 cr in new capex will come from, given rising debt and thin cash.
- Progress on regulatory approvals for the five simultaneous expansions.
- Whether the FY27 ₹274 cr revenue target survives the US tariff hit.
The full read
Natural Capsules guided ₹274 crore in revenue for FY27, aiming to reverse a ₹24.66 crore net loss. But the call exposed a funding wrinkle: the steroidal API plant now needs an extra ₹25-30 crore for clean-room facilities. That's a change from earlier claims the plant was fully capitalized. The timing is awkward. Debt is projected to climb to ₹100-110 crore through FY28 as the company pursues five expansions at once. Exports face a 68% combined US tariff on HPMC capsules, and management skipped specific margin guidance. The prior API sales target was already missed significantly. For a loss-making nano-cap, the open question is how it funds the extra capex without further straining the balance sheet.
Questions answered
- Why did Natural Capsules revise the cost of its API facility?
- During the earnings call, management disclosed that clean-room facilities for the steroidal API plant require an additional ₹25-30 crore in capital expenditure. This reverses earlier statements that the plant was already fully capitalized for such capacity.
- What is the new revenue target for FY27?
- Management provided guidance of ₹274 crore for FY27, targeting a turnaround after the company posted a net loss of ₹24.66 crore in the previous fiscal year.
- How are US tariffs affecting the business?
- The company is facing a combined 68% US tariff on its HPMC capsule exports, which the earnings call flagged as a severe headwind for that business segment.
- What is the concern around the company's capital allocation?
- Analysts questioned the ability to fund five simultaneous strategic expansions with limited cash. The company's debt profile is projected to rise to ₹100-110 crore through FY28.